



Published in final edited form as:

*Recent Pat CNS Drug Discov.* 2012 April 1; 7(1): 25–40.

## Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives

**Simone Tambaro** and **Marco Bortolato**

Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles (CA), USA

### Abstract

Rich evidence has shown that cannabis products exert a broad gamut of effects on emotional regulation. The main psychoactive ingredient of hemp,  $\Delta^9$ -tetrahydrocannabinol (THC), and its synthetic cannabinoid analogs have been reported to either attenuate or exacerbate anxiety and fear-related behaviors in humans and experimental animals. The heterogeneity of cannabis-induced psychological outcomes reflects a complex network of molecular interactions between the key neurobiological substrates of anxiety and fear and the endogenous cannabinoid system, mainly consisting of the arachidonic acid derivatives anandamide and 2-arachidonoylglycerol (2-AG) and two receptors, respectively termed CB<sub>1</sub> and CB<sub>2</sub>. The high degree of interindividual variability in the responses to cannabis is contributed by a wide spectrum of factors, including genetic and environmental determinants, as well as differences in the relative concentrations of THC and other alkaloids (such as cannabidiol) within the plant itself. The present article reviews the currently available knowledge on the herbal, synthetic and endogenous cannabinoids with respect to the modulation of anxiety responses, and highlights the challenges that should be overcome to harness the therapeutic potential of some of these compounds, all the while limiting the side effects associated with cannabis consumption.

### Keywords

cannabis; anxiety; CB receptors; endocannabinoids;  $\Delta^9$ -tetrahydrocannabinol; cannabidiol

### INTRODUCTION

Anxiety is generally defined as an emotional state characterized by maladaptive and excessive emotional responsiveness to potentially dangerous circumstances. The pathological expression of anxiety leads to enduring emotional perturbations with a consistent apprehension towards the possibility of future, vaguely defined negative events [1]. According to the current classification of anxiety disorders in the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) [2], the main diagnostic entities in this category are:

- *generalized anxiety disorder* (GAD), featuring general irritability, anxiety attacks, chronic apprehension/anxious expectation and secondary phobic avoidance.

- *panic disorder*, characterized by brief (2-10 min) spells of overwhelming anxiety or fear, accompanied by somatic and cognitive symptoms;
- *social anxiety disorder* (or social phobia), defined as extreme agitation in social contexts and avoidance of social situations;
- *obsessive-compulsive disorder* (OCD), characterized by recurrent and intrusive anxiogenic thoughts (obsessions), and stereotyped behaviors (compulsions) aimed at the reduction of the distress caused by the obsessions.
- *post-traumatic stress disorder* (PTSD), in which a prior intense trauma results in a long-lasting anxious response, with re-experiencing/flashback phenomena, avoidance and emotional numbing.

In keeping with their different clinical features and phenomenological presentations, these disorders are underpinned by divergent neurobiological alterations and respond to partially different pharmacotherapeutic strategies (outlined in Table 1). A fundamental contribution in our understanding of the neural bases of anxiety disorders and in the development of novel therapies has been afforded by animal models and testing paradigms for anxiety-like behaviors (summarized in Table 2).

Over the last decades, converging epidemiological, clinical and preclinical data have pointed to a key implication of cannabis and its endogenous system in the regulation of anxiety. In the following sections, we will present a brief synopsis on cannabinoids and the available classes of related agents, with a specific focus on their anxiolytic potential, and the scientific challenges that should be overcome to fully establish the applicability of such drugs in the therapy of anxiety disorders.

## HERBAL AND SYNTHETIC CANNABINOIDS

### Herbal cannabinoids

The three species included in the *Cannabis* genus (or sub-species, depending on the taxonomic classification; see [3], for a detailed discussion on the issue), *sativa*, *indica* and *ruderalis*, feature at least 85 unique terpenophenolic compounds, collectively named *phytocannabinoids* [4]. The main classes of phytocannabinoids are outlined in Figure 1. Quantitative analyses of cannabis constituents are usually performed by chromatographic techniques (generally Gas Chromatography, but also Thin-Layer Chromatography, or High-Performance Liquid Chromatography), often coupled with Mass Spectrometry. A detailed description of the instrumental methods used for classification and source tracing of Cannabis products (including DNA identification for forensic and intelligence purposes) is beyond the scope of this review, but can be found in [5-7].

The chemical fingerprinting of hemp products has revealed that the two most abundant phytocannabinoids are  $\Delta^9$ -tetrahydrocannabinol (THC, also named dronabinol) and cannabidiol (CBD):

The main psychoactive constituent of Cannabis, THC is a highly lipophilic alkaloid produced mainly in the leaves, flowers and glandular trichomes of the plant. Most of the pharmacological effects elicited by hemp products, including emotional and cognitive changes, analgesia, hypothermia and appetite stimulation, are considered to be reflective of the action of THC as a partial agonist of cannabinoid CB<sub>1</sub> and CB<sub>2</sub> receptors (see below). Additionally, THC has been shown to act as an acetylcholinesterase inhibitor [8-10].

In contrast with THC, CBD is not psychotropic, but has nevertheless been shown to play a role in the modulation of behavioral effects of cannabis [11]. In fact, the THC: CBD ratio is

the main criterion to define different cannabis chemotypes [12] and has been posited to contribute to the variability in neurobehavioral outcomes of marijuana or hashish consumption [13,14]. Interestingly, most cannabis strains encountered in the illegal markets generally have elevated amounts of THC [15].

The different characteristics of THC and CBD are underpinned by their distinct mechanisms of action. Whereas THC has nanomolar affinity for both CB<sub>1</sub> (K<sub>i</sub> = 25.1 nmol/L) and CB<sub>2</sub> (K<sub>i</sub> = 35.2 nmol/L) receptors, CBD exhibits much lower affinity for either target [16-20]; however, the latter phytocannabinoid was recently found to act as a highly potent antagonist/inverse agonist of both CB receptors [21], possibly due to a non-competitive mechanism of receptor blockade [22]. Additionally, CBD has been shown to exert some of its actions through other receptors, including the vanilloid receptor VR<sub>1</sub> and the serotonin receptor 5-HT<sub>1A</sub> (for a general overview of the topic, see [11]).

The other main phytocannabinoids, including cannabigerol (CBG), cannabichromene (CBC) and cannabinol (CBN) (Fig. 1) [4,23], have been shown to exert antibiotic and antiinflammatory properties, but have not been strongly associated with the behavioral effects of Cannabis; nevertheless, the recent discovery that CBG is a highly potent agonist for α<sub>2</sub> adrenoceptor and a blocker of serotonin 5-HT<sub>1A</sub> receptor [24] underscores the potential importance of these and other alkaloids in the psychoactive profile of cannabis.

### Synthetic cannabinoids

In addition to phytocannabinoids, several classes of synthetic CB receptor agonists have been developed; among these families, the best characterized are the synthetic analogs of THC - such as the bicyclic compounds CP 47,497, CP 55,244, CP 55,940 and the benzopyrans HU-210 and nabilone (Fig. 2) - and the aminoalkylindole derivatives - including WIN 55,212-2, JWH-015, JWH-018, JWH-073, JWH-081 and JWH-398 (for a general review, see [23]). Of these agents, only nabilone has been approved for clinical use as an antiemetic treatment and an adjunct analgesic for neuropathic pain [25]. Other more potent synthetic cannabinoids, such as CP 47,497, HU-210 and most JWH compounds, have regrettably gained great popularity in the market of recreational substances during the last decade, under the generic brand names of “Spice” or “K2”. Unlike THC, which is a partial agonist of CB<sub>1</sub> receptors, these agents are full, high-potency CB<sub>1</sub> receptor activators [26,27], thereby eliciting greater psychotropic effects than THC (as CB<sub>1</sub> receptors are the key mediators of the psychotropic actions of cannabis). This characteristic, together with their legal status (recently revoked across most Western countries, including USA as of March 2011) and lack of available testing procedures for the detection of urinary metabolites, has unfortunately contributed to the great diffusion of “Spice” blends in Central and Western Europe, as well as Australasia.

## ENDOCANNABINOIDS AND THEIR RECEPTORS

Following the identification of THC in the 1960s [28], extensive research was devoted to the identification of its biological targets and endogenous counterparts. Both objectives were met around 30 years later, with the characterization of the two major cannabinoid receptors, CB<sub>1</sub> [29] and CB<sub>2</sub> [30] as well as the discovery of two most prominent endocannabinoids N-arachidonylethanolamine (commonly named anandamide from the Sanskrit *ānanda*, bliss) [31] and 2-arachidonoylglycerol (2-AG) [32,33] (Fig. 3).

### CB receptors

Although CB<sub>1</sub> and CB<sub>2</sub> receptors only share 44% sequence identity (68% in the transmembrane domains), they are both coupled to G<sub>i/o</sub> proteins [34] and activated by both anandamide and 2-AG. In line with their metabotropic nature, CB receptors mediate their

intracellular response through a number of changes affecting signaling cascades, such as inhibition of adenylyl cyclase, activation of G-protein-activated inwardly rectifying potassium channels (GIRKs) and phosphorylation of extracellular signal-related kinases (ERKs) [35,36]. The distribution pattern of CB<sub>1</sub> and CB<sub>2</sub> receptors is strikingly divergent, indicating diverse physiological functions: CB<sub>1</sub> is the most abundant metabotropic receptor in the brain, and is primarily distributed in the synaptic terminals of neurons across all the major structures that regulate emotional responsiveness, perception and memory, including prefrontal cortex, amygdala, septo-hippocampal system, striatum, thalamus, brainstem nuclei etc. [37-41]. CB<sub>1</sub> receptors are typically located on presynaptic terminals [42,43], but they have also been identified in postsynaptic locations [44,45]. Presynaptic CB<sub>1</sub> receptors are posited to serve critical functions for the regulation of synaptic plasticity and neurotransmitter release; in particular, they mediate the depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE), consisting in the reduction of  $\gamma$ -amino-butyric acid (GABA) or glutamate release, respectively, from presynaptic boutons following stimulation of the postsynaptic terminals [46-49]. In general, CB<sub>1</sub> activation has been shown to inhibit the neurotransmission of other mediators, including glycine, acetylcholine, norepinephrine and serotonin [50], but the underpinnings of these phenomena have not been completely elucidated. Additionally, CB<sub>1</sub> receptors have been implicated in short- and long-term synaptic depression, in relation to phasic or tonic endocannabinoid release (for a review on these topics, see [51]).

The function of CB<sub>1</sub> receptors may vary depending on the specific interactions that they entertain with other molecular targets. For example, CB<sub>1</sub> receptors have been found to associate with other G-protein complex receptors, such as dopamine D<sub>2</sub>, orexin Ox1,  $\mu$  opioid and adenosine A<sub>2a</sub>, to form heteromeric complexes (reviewed in [52,53])

The key role of CB<sub>1</sub> receptors as mediators of neurochemical homeostasis in the brain is maintained through a complex regulation of their expression. For example, these receptors are subjected to a rapid internalization (via clathrin-coated pits) following their binding with full agonists; on the other hand, the receptors are also recycled, with a process that requires endosomal acidification and dephosphorilation [54].

While CB<sub>2</sub> receptors are abundantly expressed in most peripheral organs (and particularly in immune cells, where they regulate cytokine secretion and modulate cell trafficking) [55], their distribution in the brain appears to be sparse and particularly confined to microglial cells; nevertheless, recent evidence has revealed the presence of CB<sub>2</sub> receptors in several areas of the brain [56-58]. Interestingly, a number of studies suggest that neuronal CB<sub>2</sub> receptors may be mainly located in postsynaptic terminals [58,59]; nevertheless, the functional role of these targets in the brain remains largely elusive and awaits further characterization.

The existence of cannabinoid receptors other than CB<sub>1</sub> and CB<sub>2</sub> has been postulated based on ample experimental evidence [60-62]. Interestingly, a number of investigations have pointed to GPR55 as a novel putative cannabinoid receptor [63,64]; nevertheless, evidence on the specificity of this receptor for endocannabinoid is still inconclusive [65].

## Endocannabinoids

Both anandamide and 2-AG are derivatives of arachidonic acid, an unsaturated C<sub>20</sub> fatty acid with 4 double bonds, which also serves as the precursor for synthesis of other eicosanoids, including prostaglandins and leukotriens. Anandamide is found in picomolar concentrations and acts as a high-affinity partial agonist for both CB<sub>1</sub> and CB<sub>2</sub> receptors. It is synthesized on demand by enzymatic hydrolysis of the membrane phospholipid N-arachidonoyl phosphatidylethanolamine (NAPE), a process catalyzed by several

phospholipases [66-68]. Following release and activation of CB receptors, anandamide is rapidly removed from the synaptic cleft by a carrier-mediated system [69-72] and subsequently hydrolyzed by the membrane enzyme fatty acid amide hydrolase (FAAH) [73-75]. FAAH serves the catabolism of other substrates, including oleoylethanolamine (OEA) and palmitoylethanolamine (PEA). Both these compounds do not activate CB<sub>1</sub> receptors [76], although they may reduce or slow down anandamide degradation by competing with it for FAAH activity.

In comparison with anandamide, 2-AG is much more abundant (occurring in nanomolar concentrations across most tissues) and acts as a full agonist of both CB receptors. It is produced from 1,2-diacylglycerol (DAG) by diacylglycerol lipase (DAGL) [77] and degraded mainly by the cytosolic serine hydrolase monoacylglycerol lipase (MAGL) [78], although other enzymes are known to contribute to this process [79].

The divergent neurochemical profiles of anandamide and 2-AG underscore their different physiological roles. Although our current understanding of the different functions entertained by each endocannabinoid is still rudimentary, the development of FAAH and MAGL inhibitors [80,81] has been instrumental to elucidate the implication of each mediator in synaptic and neurochemical regulation. While 2-AG is known as the retrograde mediator of DSI [82,83] and DSE [84-87], a number of studies suggest that anandamide may serve as an activity-dependent regulator of monoaminergic transmission [88-90]. Recent evidence points to a potential biological antagonism between anandamide and 2-AG [91,92]; on the other hand, emerging evidence points to a similar role of anandamide and 2-AG in the regulation of anxiety (albeit in relation to different receptors) and pain [93]. The development of JZL195, a potent FAAH/MAGL inhibitor, has in turn revealed that the behavioral effects of CB<sub>1</sub> receptor agonists can be only recapitulated by the combination of both endocannabinoid-mediated functions [94].

Other lipids have been indicated as putative endocannabinoids, including 2-arachidonoylglycerylether (noladin ether) [95] and O-arachidonylethanolamine (virodhamine) [96] (Fig. 3). Additionally, recent evidence has identified that CB receptors may be modulated by peptidic ligands, such as hemopressin and its derivatives [97,98].

## EFFECTS OF CANNABIS AND CANNABINOID AGENTS ON ANXIETY

### Cannabis, THC and CB<sub>1</sub> receptor agonists

The employment of cannabis for its medicinal, relaxing and mood-enhancing properties has been documented across most ancient civilizations. Originally introduced in Chinese pharmacopoeia during the third millennium BCE [99,100], cannabis became a popular remedy throughout Asia and Europe in the following centuries [99,101]. The inclusion of cannabis in the medical treatises by Dioscorides and Galen secured the herb a stable reputation in the Roman Empire and the Arabic world [101]. Until the early 20<sup>th</sup> century, the plant remained a valuable therapy for a large number of diseases [102]; however, growing concerns about the psychoactive and narcotic effects of cannabis led to a progressive restriction and ultimate ban of its usage in the United States and several European countries [100,103]. Despite its illicit status, cannabis remains one of the most popular recreational drugs, particular among adolescents and young adults, in view of its mood-enhancing and euphoriant characteristics [104-106].

Most psychological and behavioral effects of marijuana and other hemp products are induced by THC through activation of CB<sub>1</sub> brain receptors. In fact, although THC and most synthetic cannabinoids are known to activate both CB<sub>1</sub> and CB<sub>2</sub> receptors, their actions on

anxiety-like behaviors and emotional regulation are efficiently countered by selective CB<sub>1</sub> receptor antagonists, such as rimonabant (see next section) [107].

The studies on the psychological effects of cannabis and THC have unfolded a highly complex and often contradictory scenario, fostering a long-standing debate on the potential harms and benefits of its products. An important aspect of this discussion (particularly in consideration of its legal aspects and the potential therapeutic applications of hemp derivatives), revolves around the distinction between use and misuse of cannabis. In particular, whereas the abuse and dependence liability of cannabis is generally well-recognized [108,109], the definition of these phenomena has been heavily criticized as reflective of political agendas rather than scientific bases. For instance, the diagnosis of substance abuse, according to the criteria listed by the DSM–IV TR, is based on the manifestation of at least one of four symptoms: interference with major professional or personal obligations; intoxication in hazardous settings; substance-related legal problems; continued use in the face of persistent social or interpersonal problems [110]. The applicability of some of these standards to marijuana and other cannabis derivatives, however, has been questioned [99], also in view of their lower potential to induce physical harm in comparison with other legal substances, such as alcohol and tobacco [111].

While the controversies surrounding cannabis are far from subdued (and are often permeated and masked by conflicting ideological credos), standardized studies on cannabinoids have highlighted that the psychological and behavioral outcomes of this substance are highly variable and range from relaxation, euthymia and heightened sociability to panic, paranoid ideation and psychosis [112-116]. A corollary of this observation is that the high comorbidity rate between cannabis use disorders and psychiatric conditions [100-105] may indicate that cannabis consumption is either a concurring cause or a “self-therapeutic” strategy for anxiety and mood disorders [117-123]. The latter interpretation is supported by the observation that anxiety-spectrum disturbances and traumas in early developmental stages are a strong predictor for later cannabis use disorders [124-127]; furthermore, several lines of evidence suggest that the anxiolytic effects of THC may partially account for the high prevalence of cannabis use in patients affected by PTSD [128-131] and OCD [132]. Accordingly, recent clinical studies have shown that THC elicits therapeutic effects in OCD [133] and trichotillomania, an impulse-control disorder characterized by compulsive hair-pulling [134]. Nevertheless, prospective analyses show that cannabis use and dependence increase the risk for development of panic disorder [135], suggesting that the effect of cannabis may vary with respect to the nosological entities within the spectrum of anxiety disorders. Of note, chronic consumption of cannabis has been hypothesized to exacerbate depressive or anxious manifestations, and reduce the therapeutic efficacy of anxiolytic agents [122,136-138]; an interesting theoretical implication of this finding is that long-term exposure to cannabinoid agents may lead to profound alterations of synaptic plasticity and neurochemical homeostasis and alter the pathophysiological trajectory of anxiety and mood disorders. Thus, while cannabis may be initially used as a self-therapy for certain anxiety disorders, the prolonged exposure to this substance in vulnerable individuals may in turn alter or aggravate the clinical course of these conditions and render the patients refractory to standard treatments.

The ability of cannabis to either exacerbate or attenuate emotional reactivity is highly influenced by numerous factors, including its chemotype, as well as the influence of genetic, developmental and contextual variables. Unfortunately, little is still known about the susceptibility factors that govern the behavioral outcomes of cannabis in patients affected by anxiety-spectrum disorders. Indeed, several components have been shown to play a role in this link, including genetic background, age, gender, environmental stress and concurrent



use of other drugs; a detailed analysis of these determinants is outside the scope of the present work, but the interested reader should refer to [139].

Aside from the influence of vulnerability factors, the available evidence indicates that cannabis, THC and other CB<sub>1</sub> receptor agonists exercise a bidirectional influence on anxiety responses as a function of the dosage. The majority of users report that consumption of modest amounts of cannabis and CB<sub>1</sub> receptor agonists results in euphoria, relaxation, heightened perception, sociability and creativity, moderate to high doses have been reported to elicit phobia, agitation, panic, dysphoria, psychotic manifestations and cognitive impairments [112-116,124,140-143]. In line with these premises, early studies showed a robust anxiolytic efficacy of low-dose nabilone in comparison with placebo [144,145]. Additionally, the few available reports on the clinical outcomes of recreational cannabinoids show that a moderate consumption of “Spice” blends is generally associated with euphoria and disinhibition [146], but the abuse of these substances is conducive to high levels of anxiety, panic, paranoid ideation and mood disturbances [147-151].

The biphasic effects of cannabinoids on anxiety-related responses have been extensively documented in rodents. In agreement with human evidence, preclinical studies have elucidated that the acute administration of low doses of CB<sub>1</sub> receptor agonists elicits anxiolytic-like in approach/avoidance tasks [152-156]; conversely, high concentrations of the same compounds are generally associated with the opposite outcomes [157-162] (for complete reviews of the topic, see [163,164])

The bidirectional action of CB<sub>1</sub> receptors on anxiety responses may be related to the modulatory role of these targets on GABA and glutamate release across amygdala and other forebrain areas [41,165,166]. As these two major neurotransmitters affect anxiety in an opposite fashion, different doses of cannabinoids and synthetic CB<sub>1</sub> receptor agonists may indeed produce highly divergent effects, in relation to their ability to affect the homeostasis and the balance of GABA and glutamate (for a review on these issues, see [163]). Furthermore, CB<sub>1</sub> receptors have been shown to play critical roles in the regulation of most neurochemical substrates of anxiety, including the neurotransmitters serotonin, norepinephrine and acetylcholine, as well as stress hormones, coilecystokynin and opioid peptides [50,163].

In line with this concept, the infusion in the periaqueductal grey of arachidonyl-2-chloroethylamide (ACEA), an anandamide synthetic analog with high CB<sub>1</sub> receptor selectivity, elicited anxiolytic-like effects in rats in an elevated plus maze, with a bell-shaped dose-response curve [167], the highest doses being associated to no significant behavioral change. Novel categories of compounds have been patented for potential efficacy as selective CB<sub>1</sub> receptor modulators, including sulfonyl-benzamides [168] and tetrasubstituted imidazole derivatives [169]. To the best of our knowledge, however, no findings on the action of these compounds in anxiety regulation have been reported to date.

### **CB<sub>1</sub> receptor antagonists/inverse agonists**

The cannabinoid CB<sub>1</sub> receptor antagonists/inverse agonist rimonabant was introduced into clinical practice by Sanofi-Aventis in 2006 as a treatment for obesity [170] and smoking cessation [171]. The majority of preclinical studies found that these compounds are anxiogenic at high doses [158,159,172,173] and ineffective at low doses [174,175]. The anxiogenic properties of CB<sub>1</sub> antagonists, were unequivocally confirmed by clinical data on the psychiatric side effects of rimonabant. The significant increase in anxiety, depression and suicidality in patients under treatment with rimonabant [176-179], in particular, led to the withdrawal of the drug from the European market in October, 2008. As a consequence, several pharmaceutical companies announced the interruption of their clinical research on

CB<sub>1</sub> receptor antagonists, including taranabant (from Merck) and otenabant (from Pfizer), both in Phase 3 of development. Some of the anxiogenic properties of rimonabant and analogs have been speculated to be due to their activity as inverse agonists; as a result, the therapeutic use of newly-developed neutral CB<sub>1</sub> antagonists has been proposed, with the hypothesis that these compounds would not elicit the untoward psychological effects observed with rimonabant and its analogs [180,181]; this idea is supported by recent findings, showing that unlike CB<sub>1</sub> receptor inverse agonists, the neutral antagonists of this targets fail to facilitate the acquisition or consolidation of fear [182].

### CB<sub>2</sub> receptor ligands

Few studies have actually evaluated the role of CB<sub>2</sub> receptor in anxiety and stress response. While this receptor was posited to be mainly expressed mainly in immune cells and peripheral areas, its identification in the brain under pathological conditions, such as Alzheimer's disease, multiple sclerosis and amyotrophic lateral sclerosis spinal cord [183-185], led to a number of studies aimed at the assessment of its potential role in brain function and behavioral regulation. Some of these investigations indicated that the suppression of CB<sub>2</sub> receptor in the brain, through intracerebroventricular injection of antisense nucleotide sequences, elicited anxiolytic effects in rodents [186]. In contrast, Garcia-Gutierrez and Manzanares [187] recently described that the overexpression of CB<sub>2</sub> receptors reduced anxiogenic-related behaviors in the light-dark box and elevated plus maze. These premises point to the possibility that CB<sub>2</sub> receptor ligands may also play a role in the modulation of anxiety disorders. This hypothesis, however, awaits further examination with proper pharmacological tools.

### CBD

Several studies suggest that THC and CBD may exert opposite actions on brain function and psychopathology [188], possibly in relation to the action of CBD as a potent CB<sub>1</sub> receptor antagonist/inverse agonist [21] (see above). Several lines of preclinical work have shown that CBD reduces the effects of THC on several behavioral functions [189-191]. In line with these data, CBD has been found to reduce the anxiety and improve the sensation of well being induced by an acute, high THC dose in healthy volunteers [192].

In contrast with these data, a number of studies have shown that CBD pretreatment potentiated the behavioral effects induced by THC [193-195]. These actions may signify the ability of CBD to inhibit cytochrome P450-mediated drug metabolism [196,197], which may increase THC blood and brain concentrations [193,195].

Notably, the behavioral outcomes of CBD do not appear to be only due to potential pharmacodynamic/pharmacokinetic competition with THC; indeed, recent studies have shown that CBD exerts inherent anxiolytic effects, both in rodent models [157,198-201] and, more recently, in patients affected by social phobia [202,203]. The anxiolytic action of CBD may be linked to 5-HT<sub>1A</sub> receptor, but not through benzodiazepine receptors [204]. Of note, the anxiolytic action of CBD also appears to be bidirectional, as only low to moderate doses, but not high doses, have been associated with exert anxiolytic effects [200,205].

The anxiolytic action of CBD do not appear to be mediated by benzodiazepine receptors [204], but rather by 5-HT<sub>1A</sub> serotonin receptors in the bed nucleus of the stria terminalis [206], a critical component of the amygdaloid complex involved in the regulation of stress response.

Accordingly, CBD has been shown to reduce amygdalar responses to fearful stimuli [207]; this mechanism may be essential for the anxiolytic effects of this compound in social phobia [203]. Furthermore, CBD has been shown to elicit antipanic effects through the activation of



5-HT<sub>1A</sub> receptors in the dorsal periaqueductal gray, a critical area for the modulation of emotional reactivity to stress [208,209].

### Endocannabinoid transport blockers

The systemic administration of the endocannabinoid transport blocker AM404 (Fig. 4) was shown to elicit anxiolytic-like behaviors in the elevated plus maze and defensive withdrawal in adult rats, as well as an attenuation of ultrasonic vocalizations in rat pups [175]. The same compound was shown to attenuate marble burying (a paradigm for compulsivity testing) in mice, suggesting that this compound may have some potential efficacy for OCD [206]. Interestingly, the anxiolytic effects of AM404 were shown to be contributed by both CB<sub>1</sub> and 5-HT<sub>1A</sub> receptors [152,210], in a fashion similar to the potent CB<sub>1</sub> receptor agonist CP 55,940 [160]. Additionally, AM404 has been suggested to act as a FAAH inhibitor [211], although evidence in this respect is controversial [72]. Indeed, despite the identification of potential candidate endocannabinoid binding sites [212], no final evidence is currently available on the existence and/or molecular identity of the endocannabinoid transporter.

Although the possibility of targeting the endocannabinoid carrier for the development of anxiolytic compounds is appealing and has been targeted by a patent proposing these compounds as a pharmacological support for psychotherapy [213], the elusive molecular identity of the transporter itself has greatly limited the studies. Furthermore, preliminary data indicate that AM404 elicits reward in animals and is self-administered by squirrel monkeys [175,214], raising the possibility that endocannabinoid transport blockers may be addictive.

### FAAH inhibitors

The prototypical FAAH inhibitor URB597 (Fig. 4) has been shown to reduce anxiety-like behaviors in rats, in a rimonabant-sensitive fashion [155,163,215-217]. In addition to its anxiolytic-like properties, URB597 was found to exert also antidepressant-like effects in several animal models with high face and predictive validity, such as the forced swim, tail suspension and chronic mild stress paradigms [89,210,216,218]. The anxiolytic action of FAAH inhibitors has been suggested to depend on the enhancement of anandamide in the dorsolateral periaqueductal gray [219]; interestingly, however, only low doses of URB597 in the prefrontal cortex were found to elicit anxiolytic-like effects, through CB<sub>1</sub> receptor activation. However, higher doses ceased to elicit anxiolysis, in view of their interaction with TP<sub>1V</sub> vanilloid receptors [220]. Furthermore, the anxiolytic and antidepressant actions of FAAH inhibitors were observed only under conditions of high environmental aversiveness, but not under normal conditions [163,218,221]. Importantly, the psychotropic effects of FAAH inhibitors are partially distinct from those associated with cannabinoids, in that they appear to fail to reproduce the hedonic and interoceptive states produced by CB receptor agonists [89] and to induce self-administration in squirrel monkeys [222]. Taken together, these data suggest that FAAH inhibitors may be promising tools in the therapy of anxiety and mood disorders with a safer profile than cannabinoid direct agonists. This idea has been recently endorsed by several authors in recent articles and patents, featuring novel categories of highly selective and potent FAAH inhibitors [223-225] [226]. However, it should be noted that recent data have recently shown that URB597 induce a number of side effects in rats, including social withdrawal, working memory deficits [227] and impairments in auditory discrimination and reversal of olfactory discrimination [228].

### MAGL inhibitors

The role of 2-AG in emotional regulation has been difficult to ascertain until the recent development of highly selective monoacylglycerol lipase (MAGL) inhibitors [35,223]. Several lines of evidence have suggested that 2-AG plays a pivotal role in the

pathophysiology of anxiety and defensive behaviors. The prototypical MAGL inhibitor, JZL184 (Fig. 4), has been shown to enhance the levels of 2-AG, but not anandamide; this effect is due to its extremely high selectivity for MAGL over FAAH and other brain serine hydrolases. Recent evidence has shown that this compound exerts anxiolytic-like effects in the elevated plus maze and in marble burying, at doses that do not affect locomotor activity [93,229,230]. Similarly to the effects described for FAAH inhibitors (see above), the anxiolytic effects of this compound were observed in highly aversive (or anxiogenic) contextual settings [229]. The neurobiological role of 2-AG in anxiety is still poorly understood, although several studies have shown that environmental stressors alter its biosynthesis and degradation in key brain structures controlling emotional regulation, including periaqueductal grey, amygdala and hippocampus [231,232]. Interestingly, recent evidence has shown that the anxiolytic properties of JZL184 appear to be mediated by CB<sub>2</sub>, rather than CB<sub>1</sub> receptors [93], pointing to a potential implication of this receptor in the role of 2-AG in anxiety regulation.

## CURRENT AND FUTURE DEVELOPMENTS

In light of the limitations of our current pharmacological armamentarium for anxiety disorders, the ability of cannabinoids to modulate emotional responses is extremely attractive for the development of novel anxiolytic agents [217]. At the same time, great concern arises from the protean role of cannabinoids on the regulation of these responses, as well as their misuse liability and other side effects. The identification of operational strategies for the employment of cannabinoids in the therapy of anxiety disorders is therefore a fundamental goal in psychiatry research.

As outlined above, clinical evidence strongly suggests that acute administration of low doses of CB<sub>1</sub> receptor agonists results in anxiolytic effects, while excessive activation of these targets elicits opposite outcomes, following a reverse U-shaped dose-response pattern. Hence, a primary strategy to harness the anxiolytic properties of cannabinoids could consist in the employment of partial, low-affinity CB<sub>1</sub> agonists, which may ensure a relatively high therapeutic index and the stabilization of the activation of this target within a range associated with mood enhancement and/or anxiolysis. This idea is indirectly supported by the mirroring observation that anecdotal reports on highly potent, high-affinity synthetic cannabinoids (such as those contained in “Spice” blends) trigger greater psychoactive effects than the partial CB agonist THC [26]. This concept indicates a potential evolution in the search for direct CB agonists, in sharp contrast with the previous trend aimed at the identification of high-affinity CB receptor activators.

An alternative strategy to achieve a similar therapeutic goal may lie in the combination of CB<sub>1</sub> receptor agonists with low dosages of antagonists (preferably neutral, in order to avoid potential side effects linked to CB<sub>1</sub> inverse agonism); this intriguing approach, which has been indicated in a recent patent [233], is based on the likely mechanism of action of Sativex®, a cannabinoid mouth spray containing THC and CBD (in a ratio of 1.08:1) and marketed for the treatment of neuropathic pain, spasticity and overactive bladder, in consideration of the action of CBD as a CB<sub>1</sub> receptor antagonist. However, recent preliminary clinical studies have shown that this formulation did not significantly reduce anxiety (in fact, it was reported to induce a mild, yet not significant increase of this symptom) [234,235], and that CBD did not appear to elicit a significant opposition to the effect of dronabinol [235], plausibly indicating that a higher concentration of this ingredient (or lower relative amount of THC) may be necessary to elicit anxiolytic effects.

A third, highly promising avenue for the development of cannabinoid-based anxiolytic therapies may be afforded by FAAH inhibitors. Unlike endocannabinoid transport blockers

and direct CB receptor agonists, these compounds exhibit a number of highly desirable properties for anxiolytic agents: first, they appear to maintain their anxiolytic and antidepressant effect not only under conditions of acute administration, but also following long-term treatment [93,210]; second, they appear to elicit their effects only in conditions of highly aversive environmental circumstances (i.e., similar to those that would in fact require an anxiolytic treatment); third, they have no apparent addiction liability [89,222]. The neurobiological bases of this phenomenon are not completely understood, and may be related to the involvement of other FAAH substrates, such as OEA or PEA; however, recent investigations suggest that the lack of 2-AG enhancement ensuing FAAH inactivation may contribute to the lack of reinforcing properties of URB597 [236], potentially suggesting a different role of anandamide and 2-AG in the modulation of reward; this idea is actually consistent with the recent finding that 2-AG induces self-administration in monkeys [237].

A key problem concerning the potential application of cannabinoid-related agents and cannabinoids is the relatively little information about their long-term effects following chronic administration. Indeed, the subjective effects of cannabis have been shown to be typically different in chronic users as compared to occasional marijuana smokers [238,239]. Prolonged consumption of cannabis has been shown to induce affective sequelae, including alexithymia and avolition [113,240-242]. Interestingly, tolerance has been shown to the effects of THC [243,244], while no information is available on endocannabinoid-related agents. Long-term administration of cannabinoids has been shown to result in a number of neuroplastic adaptive processes, including CB receptor down-regulation [245,246]. Some of these phenomena may indeed be critical in shaping the different emotional responsiveness to cannabis throughout life and reflect a potential pathophysiological loop which may compound the severity of pre-existing anxiety and affective disorders.

Finally, another important step for the employment of cannabinoid-based anxiolytic therapies will be the analysis of the vulnerability factors implicated in the differential responses and long-term sequelae induced by cannabis consumption. For example, numerous meta-analyses and longitudinal studies have established that cannabis consumption in adolescence is conducive to an increased risk for psychotic disorders [247-250]. This association is particularly significant in the presence of other genetic factors, such as the Val<sup>108</sup>Met allelic variant of the gene encoding Catechol-O-methyltransferase (COMT) [251,252], one of the main enzymes for the degradation of the neurotransmitter dopamine. Interestingly, it has been shown that the synergistic effect of COMT haplotype and cannabis in adolescence is more robust in conjunction with predisposing environmental variables, such as the exposure to urbanicity and psychosocial stress [253]. Another gene that may modulate the behavioral responsiveness to cannabinoids is *Nrg1*, which encodes for the synaptic protein neuregulin 1. Indeed, the heterozygous deletion of this gene ablates the development of tolerance to the anxiogenic effects of CB receptor agonists [254,255]. These findings suggest that the employment of a pharmacogenetic approach may be a critical screening instrument to identify which patients may be treated with cannabis for medical purposes without risks of neuropsychiatric side effects. Notably, the role of genes in the mental sequelae of cannabis may also be contributed by epigenetic factors, in consideration of the recent finding that THC induces expression of histone deacetylase 3 [256].

While studies on the biological determinants of different responses to cannabis are still at their preliminary stages, advances in this area may be essential to allow a personalized approach for the employment of cannabinoid-based therapies in anxiety and mood disorders.

## Acknowledgments

The present work was supported by the National Institute of Health grant R21HD070611 and the USC Zumberge Individual Research Grant (to MB).

## REFERENCES

1. Nutt D, Allgulander C, Lecrubier Y, Peters T, Wittchen U. Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting. *J Psychopharmacol.* 2008; 22(4): 409–16. [PubMed: 18635721]
2. Sugiura T, Waku K. 2-Arachidonoylglycerol and the cannabinoid receptors. *Chem Phys Lipids.* 2000; 108(1-2):89–106. [PubMed: 11106784]
3. Hillig KW, Mahlberg PG. A chemotaxonomic analysis of cannabinoid variation in *Cannabis* (Cannabaceae). *Am J Bot.* 2004; 91(6):966–75. [PubMed: 21653452]
4. ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. *Life sciences.* 2005; 78(5):539–48. [PubMed: 16199061]
5. Brenneisen, R. Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents. In: ElSohly, MA., editor. *Marijuana and the Cannabinoids.* Humana Press; 2007. p. 17-49.
6. ElSohly, MA.; Stanford, DF.; Murphy, TP. Chemical Fingerprinting of Cannabis as a Means of Source Identification. In: ElSohly, MA., editor. *Marijuana and the Cannabinoids.* Humana Press; 2007. p. 51-66.
7. Miller Coyle H, Palmbach T, Juliano N, Ladd C, Lee HC. An overview of DNA methods for the identification and individualization of marijuana. *Croatian medical journal.* 2003; 44(3):315–21. [PubMed: 12808725]
8. Brown H. Possible anticholinesterase-like effects of trans(-) 8 and - 9 tetrahydrocannabinol as observed in the general motor activity of mice. *Psychopharmacologia.* 1972; 27(2):111–6. [PubMed: 4638205]
9. Yoshimura H, Fujiwara M, Ueki S. Biochemical correlates in mouse-killing behavior of the rat: brain acetylcholine and acetylcholinesterase after administration of delta9-tetrahydrocannabinol. *Brain research.* 1974; 81(3):567–70. [PubMed: 4474050]
10. Mishima K, Egashira N, Matsumoto Y, Iwasaki K, Fujiwara M. Involvement of reduced acetylcholine release in Delta9-tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze. *Life sciences.* 2002; 72(4-5):397–407. [PubMed: 12467880]
11. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. *Rev Bras Psiquiatr.* 2008; 30(3):271–80. [PubMed: 18833429]
12. de Meijer EPM, Kamp HJ, Eeuwijk FA. Characterisation of Cannabis accessions with regard to cannabinoid content in relation to other plant characters. *Euphytica.* 1992; 62(3):187–200.
13. Fadda P, Robinson L, Fratta W, Pertwee RG, Riedel G. Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. *Neuropharmacology.* 2004; 47(8):1170–9. [PubMed: 15567426]
14. Ryan D, Drysdale AJ, Pertwee RG, Platt B. Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. *Neurosci Lett.* 2006; 408(3):236–41. [PubMed: 16997463]
15. Starks, M. *Marijuana chemistry: genetics, processing & potency.* Ronin Publishing, Inc.; Oakland, USA: 1990.
16. Showalter VM, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. *J Pharmacol Exp Ther.* 1996; 278(3):989–99. [PubMed: 8819477]
17. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. *J Pharmacol Exp Ther.* 1998; 285(1):285–92. [PubMed: 9536023]
18. Pertwee RG. Pharmacology of cannabinoid receptor ligands. *Curr Med Chem.* 1999; 6(8):635–64. [PubMed: 10469884]

19. Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol.* 2001; 134(4):845–52. [PubMed: 11606325]
20. Thomas A, Ross RA, Saha B, Mahadevan A, Razdan RK, Pertwee RG. 6''-Azidohept-2''-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. *Eur J Pharmacol.* 2004; 487(1-3):213–21. [PubMed: 15033394]
21. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. *Br J Pharmacol.* 2007; 150(5):613–23. [PubMed: 17245363]
22. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. *Br J Pharmacol.* 2008; 153(2):199–215. [PubMed: 17828291]
23. Fisar Z. Phytocannabinoids and endocannabinoids. *Curr Drug Abuse Rev.* 2009; 2(1):51–75. [PubMed: 19630737]
24. Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. *Br J Pharmacol.* 2010; 159(1):129–41. [PubMed: 20002104]
25. Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. *Expert Opin Investig Drugs.* 2008; 17(1):85–95.
26. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. *Br J Pharmacol.* 2010; 160(3):585–93. [PubMed: 20100276]
27. Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K. CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. *Eur J Pharmacol.* 2011; 659(2-3):139–45. [PubMed: 21333643]
28. Gaoni Y, Mechoulam R. Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish. *J Amer Chem Soc.* 1964; 86:1646–7.
29. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature.* 1990; 346(6284):561–4. [PubMed: 2165569]
30. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature.* 1993; 365(6441):61–5. [PubMed: 7689702]
31. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science.* 1992; 258(5090):1946–9. [PubMed: 1470919]
32. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol.* 1995; 50(1):83–90. [PubMed: 7605349]
33. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem Biophys Res Commun.* 1995; 215(1):89–97. [PubMed: 7575630]
34. Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. *Mol Pharmacol.* 1986; 29(3):307–13. [PubMed: 2869405]
35. Adamec R. Transmitter systems involved in neural plasticity underlying increased anxiety and defense--implications for understanding anxiety following traumatic stress. *Neurosci Biobehav Rev.* 1997; 21(6):755–65. [PubMed: 9415900]
36. Demuth DG, Molleman A. Cannabinoid signalling. *Life sciences.* 2006; 78(6):549–63. [PubMed: 16109430]
37. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. *Proc Natl Acad Sci U S A.* 1990; 87(5):1932–6. [PubMed: 2308954]
38. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. *J Neurosci.* 1991; 11(2):563–83. [PubMed: 1992016]



39. Charney DS, Deutch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. *Crit Rev Neurobiol*. 1996; 10(3-4):419–46. [PubMed: 8978989]
40. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience*. 1997; 77(2):299–318. [PubMed: 9472392]
41. Katona I, Rancz EA, Acsady L, Ledent C, Mackie K, Hajos N, et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2001; 21(23):9506–18. [PubMed: 11717385]
42. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. *Physiol Rev*. 2003; 83(3):1017–66. [PubMed: 12843414]
43. Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. *Handb Exp Pharmacol*. 2005; (168):299–325. [PubMed: 16596779]
44. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. *Neuroscience*. 1998; 83(2):393–411. [PubMed: 9460749]
45. Salio C, Fischer J, Franzoni MF, Conrath M. Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. *Neuroscience*. 2002; 110(4):755–64. [PubMed: 11934482]
46. Morishita W, Alger BE. Evidence for endogenous excitatory amino acids as mediators in DSI of GABA(A)ergic transmission in hippocampal CA1. *J Neurophysiol*. 1999; 82(5):2556–64. [PubMed: 10561426]
47. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. *Nature*. 2001; 410(6828):588–92. [PubMed: 11279497]
48. Ohno-Shosaku T, Maejima T, Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. *Neuron*. 2001; 29(3):729–38. [PubMed: 11301031]
49. Varma N, Carlson GC, Ledent C, Alger BE. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. *J Neurosci*. 2001; 21(24):RC188. [PubMed: 11734603]
50. Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. *Handb Exp Pharmacol*. 2005; (168):327–65. [PubMed: 16596780]
51. Lovinger DM. Endocannabinoid Signaling in Neural Plasticity. *Pharmacology of Neurotransmitter Release*. 2008; 184:435–77.
52. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. *Pharmacological reviews*. 2010; 62(4):588–631. [PubMed: 21079038]
53. Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI, et al. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in “herbal high” products. *J Anal Toxicol*. 2010; 34(5):252–60. [PubMed: 20529459]
54. Hsieh C, Brown S, Derleth C, Mackie K. Internalization and Recycling of the CB1 Cannabinoid Receptor. *Journal of Neurochemistry*. 1999; 73(2):493–501. [PubMed: 10428044]
55. Walter L, Stella N. Cannabinoids and neuroinflammation. *Br J Pharmacol*. 2004; 141(5):775–85. [PubMed: 14757702]
56. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. *Science*. 2005; 310(5746):329–32. [PubMed: 16224028]
57. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. *Brain research*. 2006; 1071(1):10–23. [PubMed: 16472786]
58. Onaivi ES. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. *Neuropsychobiology*. 2006; 54(4):231–46. [PubMed: 17356307]

59. Brusco A, Tagliaferro P, Saez T, Onaivi ES. Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus. *Synapse*. 2008; 62(12):944–9. [PubMed: 18798269]
60. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. *Mol Pharmacol*. 2001; 60(1):155–63. [PubMed: 11408610]
61. O’Sullivan SE, Kendall DA, Randall MD. Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. *Br J Pharmacol*. 2004; 142(3):435–42. [PubMed: 15148250]
62. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, et al. Evidence for novel cannabinoid receptors. *Pharmacol Ther*. 2005; 106(2):133–45. [PubMed: 15866316]
63. Sjögren, S.; Ryberg, E.; Lindblom, A.; Larsson, N.; Åstrand, A.; Hjorth, S., et al. A new receptor for cannabinoid ligands; Symposium on the Cannabinoids; International Cannabinoid Research Society, Burlington, Vermont, USA. 2005;
64. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. *Proc Natl Acad Sci U S A*. 2008; 105(7):2699–704. [PubMed: 18263732]
65. Brown AJ, Robin Hiley C. Is GPR55 an anandamide receptor? *Vitam Horm*. 2009; 81:111–37. [PubMed: 19647110]
66. Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. *J Biol Chem*. 2004; 279(7):5298–305. [PubMed: 14634025]
67. Sun YX, Tsuboi K, Okamoto Y, Tonai T, Murakami M, Kudo I, et al. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. *Biochem J*. 2004; 380(Pt 3):749–56. [PubMed: 14998370]
68. Liu C, Walker JM. Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain. *J Neurophysiol*. 2006; 96(6):2984–94. [PubMed: 16943316]
69. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. *Nature*. 1994; 372(6507):686–91. [PubMed: 7990962]
70. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. *Science*. 1997; 277(5329):1094–7. [PubMed: 9262477]
71. Hillard CJ, Campbell WB. Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. *J Lipid Res*. 1997; 38(12):2383–98. [PubMed: 9458263]
72. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. *Proc Natl Acad Sci U S A*. 2004; 101(23):8756–61. [PubMed: 15138300]
73. Hillard CJ, Wilkison DM, Edgmond WS, Campbell WB. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. *Biochim Biophys Acta*. 1995; 1257(3):249–56. [PubMed: 7647100]
74. Ueda N, Yamamoto K, Yamamoto S, Tokunaga T, Shirakawa E, Shinkai H, et al. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. *Biochim Biophys Acta*. 1995; 1254(2):127–34. [PubMed: 7827116]
75. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature*. 1996; 384(6604):83–7. [PubMed: 8900284]
76. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. *Life sciences*. 2005; 77(14):1685–98. [PubMed: 15963531]
77. Bisogno T, Howell F, Williams G, Minassi A, Cascio MG, Ligresti A, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J Cell Biol*. 2003; 163(3):463–8. [PubMed: 14610053]
78. Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. *Chem Phys Lipids*. 2002; 121(1-2):149–58. [PubMed: 12505697]

79. Kozak KR, Prusakiewicz JJ, Marnett LJ. Oxidative metabolism of endocannabinoids by COX-2. *Curr Pharm Des.* 2004; 10(6):659–67. [PubMed: 14965328]
80. Piomelli D. The endocannabinoid system: a drug discovery perspective. *Curr Opin Investig Drugs.* 2005; 6(7):672–9.
81. Hohmann AG. Inhibitors of monoacylglycerol lipase as novel analgesics. *Br J Pharmacol.* 2007; 150(6):673–5. [PubMed: 17293886]
82. Kim J, Alger BE. Inhibition of cyclooxygenase-2 potentiates retrograde endocannabinoid effects in hippocampus. *Nat Neurosci.* 2004; 7(7):697–8. [PubMed: 15184902]
83. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G, et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. *Nat Neurosci.* 2005; 8(9):1139–41. [PubMed: 16116451]
84. Gerdeman GL, Ronesi J, Lovinger DM. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. *Nat Neurosci.* 2002; 5(5):446–51. [PubMed: 11976704]
85. Robbe D, Alonso G, Chaumont S, Bockaert J, Manzoni OJ. Role of p/q-Ca<sup>2+</sup> channels in metabotropic glutamate receptor 2/3-dependent presynaptic long-term depression at nucleus accumbens synapses. *J Neurosci.* 2002; 22(11):4346–56. [PubMed: 12040040]
86. Sjostrom PJ, Turrigiano GG, Nelson SB. Neocortical LTD via coincident activation of presynaptic NMDA and cannabinoid receptors. *Neuron.* 2003; 39(4):641–54. [PubMed: 12925278]
87. Jung KM, Mangieri R, Stapleton C, Kim J, Fegley D, Wallace M, et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. *Mol Pharmacol.* 2005; 68(5):1196–202. [PubMed: 16051747]
88. Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. *Nat Neurosci.* 1999; 2(4):358–63. [PubMed: 10204543]
89. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. *Proc Natl Acad Sci U S A.* 2005; 102(51):18620–5. [PubMed: 16352709]
90. Muntoni AL, Pillolla G, Melis M, Perra S, Gessa GL, Pistis M. Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons. *Eur J Neurosci.* 2006; 23(9):2385–94. [PubMed: 16706846]
91. Di Marzo V, Cristino L. Why endocannabinoids are not all alike. *Nat Neurosci.* 2008; 11(2):124–6. [PubMed: 18227793]
92. Maccarrone M, Rossi S, Bari M, De Chiara V, Fezza F, Musella A, et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. *Nat Neurosci.* 2008; 11(2):152–9. [PubMed: 18204441]
93. Busquets-Garcia A, Puighermanal E, Pastor A, de la Torre R, Maldonado R, Ozaita A. Differential Role of Anandamide and 2-Arachidonoylglycerol in Memory and Anxiety-like Responses. *Biological psychiatry.* 2011; 70(5):479–86. [PubMed: 21684528]
94. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. *Nat Chem Biol.* 2009; 5(1):37–44. [PubMed: 19029917]
95. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, et al. 2-arachidonoyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. *Proc Natl Acad Sci U S A.* 2001; 98(7):3662–5. [PubMed: 11259648]
96. Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, et al. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. *J Pharmacol Exp Ther.* 2002; 301(3):1020–4. [PubMed: 12023533]
97. Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL, et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. *Proc Natl Acad Sci U S A.* 2007; 104(51):20588–93. [PubMed: 18077343]
98. Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS, et al. Novel endogenous peptide agonists of cannabinoid receptors. *FASEB J.* 2009; 23(9):3020–9. [PubMed: 19380512]

99. Earlywine, M. Understanding marijuana. A new look at the scientific evidence. Oxford University Press; New York: 2002.
100. Aggarwal SK, Carter GT, Sullivan MD, ZumBrunnen C, Morrill R, Mayer JD. Medicinal use of cannabis in the United States: historical perspectives, current trends, and future directions. *Journal of opioid management*. 2009; 5(3):153–68. [PubMed: 19662925]
101. Fankhauser, M. History of cannabis in Western Medicine. Cannabis and Cannabinoids. The Haworth Integrative Healing Press; New York: 2002. p. 37-51.
102. Hanus LO. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. *Medicinal research reviews*. 2009; 29(2):213–71. [PubMed: 18777572]
103. Escobedo, A. Historia general de las drogas. Espasa Calpe; Madrid: 1998.
104. Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. *Addiction*. 1998; 93(6):837–46. [PubMed: 9744119]
105. Boys A, Marsden J, Griffiths P, Fountain J, Stillwell G, Strang J. Substance use among young people: the relationship between perceived functions and intentions. *Addiction*. 1999; 94(7): 1043–50. [PubMed: 10707442]
106. Latimer W, Zur J. Epidemiologic trends of adolescent use of alcohol, tobacco, and other drugs. *Child and adolescent psychiatric clinics of North America*. 2010; 19(3):451–64. [PubMed: 20682214]
107. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. *FEBS Lett*. 1994; 350(2-3): 240–4. [PubMed: 8070571]
108. Kendler KS, Prescott CA. Cannabis use, abuse, and dependence in a population-based sample of female twins. *The American journal of psychiatry*. 1998; 155(8):1016–22. [PubMed: 9699687]
109. Swift W, Hall W, Teesson M. Cannabis use and dependence among Australian adults: results from the National Survey of Mental Health and Wellbeing. *Addiction*. 2001; 96(5):737–48. [PubMed: 11331032]
110. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.. American Psychiatric Association Press; Washington: 2000.
111. Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU. Generalized anxiety disorder: comorbidity, comparative biology and treatment. *Int J Neuropsychopharmacol*. 2002; 5(4):315–25. [PubMed: 12466031]
112. Hollister LE. Health aspects of cannabis. *Pharmacol Rev*. 1986; 38(1):1–20. [PubMed: 3520605]
113. Hall W, Solowij N. Adverse effects of cannabis. *Lancet*. 1998; 352(9140):1611–6. [PubMed: 9843121]
114. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. *BMJ*. 2002; 325(7374):1195–8. [PubMed: 12446533]
115. Green B, Kavanagh D, Young R. Being stoned: a review of self-reported cannabis effects. *Drug Alcohol Rev*. 2003; 22(4):453–60. [PubMed: 14660135]
116. Dannon PN, Lowengrub K, Amiaz R, Grunhaus L, Kotler M. Comorbid cannabis use and panic disorder: short term and long term follow-up study. *Hum Psychopharmacol*. 2004; 19(2):97–101. [PubMed: 14994319]
117. Gruber AJ, Pope HG Jr, Brown ME. Do patients use marijuana as an antidepressant? *Depression*. 1996; 4(2):77–80. [PubMed: 9160645]
118. Stewart SH, Karp J, Pihl RO, Peterson RA. Anxiety sensitivity and self-reported reasons for drug use. *J Subst Abuse*. 1997; 9:223–40. [PubMed: 9494951]
119. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research. *J Psychoactive Drugs*. 1998; 30(2):171–7. [PubMed: 9692379]
120. Ogborne AC, Smart RG, Adlaf EM. Self-reported medical use of marijuana: a survey of the general population. *CMAJ*. 2000; 162(12):1685–6. [PubMed: 10870496]
121. Agosti V, Nunes E, Levin F. Rates of psychiatric comorbidity among U. *Am J Drug Alcohol Abuse*. 2002; 28(4):643–52. [PubMed: 12492261]

122. Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. *J Psychopharmacol.* 2005; 19(3):293–300. [PubMed: 15888515]
123. Arendt M, Rosenberg R, Fjordback L, Brandholdt J, Foldager L, Sher L, et al. Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects. *Psychol Med.* 2007; 37(7):935–45. [PubMed: 17202003]
124. Tournier M, Sorbara F, Gindre C, Swendsen JD, Verdoux H. Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population. *Psychiatry Res.* 2003; 118(1):1–8. [PubMed: 12759155]
125. Wittchen HU, Frohlich C, Behrendt S, Gunther A, Rehm J, Zimmermann P, et al. Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. *Drug Alcohol Depend.* 2007; 88(Suppl 1):S60–70. [PubMed: 17257779]
126. Bonn-Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. *J Trauma Stress.* 2007; 20(4):577–86. [PubMed: 17721963]
127. Buckner JD, Schmidt NB, Lang AR, Small JW, Schlauch RC, Lewinsohn PM. Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. *J Psychiatr Res.* 2008; 42(3):230–9. [PubMed: 17320907]
128. Bremner JD, Southwick SM, Darnell A, Charney DS. Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse. *Am J Psychiatry.* 1996; 153(3):369–75. [PubMed: 8610824]
129. Jacobsen LK, Southwick SM, Kosten TR. Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. *Am J Psychiatry.* 2001; 158(8):1184–90. [PubMed: 11481147]
130. Reynolds M, Mezey G, Chapman M, Wheeler M, Drummond C, Baldacchino A. Co-morbid post-traumatic stress disorder in a substance misusing clinical population. *Drug Alcohol Depend.* 2005; 77(3):251–8. [PubMed: 15734225]
131. Cogle JR, Bonn-Miller MO, Vujanovic AA, Zvolensky MJ, Hawkins KA. Posttraumatic stress disorder and Cannabis use in a nationally representative sample. *Psychol Addict Behav.* 2011
132. Fontenelle LF, Hasler G. The analytical epidemiology of obsessive-compulsive disorder: risk factors and correlates. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008; 32(1):1–15. [PubMed: 17689849]
133. Schindler F, Angheliescu I, Regen F, Jockers-Scherubl M. Improvement in refractory obsessive compulsive disorder with dronabinol. *Am J Psychiatry.* 2008; 165(4):536–7. [PubMed: 18381920]
134. Grant JE, Odlaug BL, Chamberlain SR, Kim SW. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. *Psychopharmacology.* 2011
135. Zvolensky MJ, Lewinsohn P, Bernstein A, Schmidt NB, Buckner JD, Seeley J, et al. Prospective associations between cannabis use, abuse, and dependence and panic attacks and disorder. *J Psychiatr Res.* 2008; 42(12):1017–23. [PubMed: 18076905]
136. Strakowski SM, DelBello MP, Fleck DE, Arndt S. The impact of substance abuse on the course of bipolar disorder. *Biological psychiatry.* 2000; 48(6):477–85. [PubMed: 11018221]
137. Baethge C, Baldessarini RJ, Khalsa HM, Hennen J, Salvatore P, Tohen M. Substance abuse in first-episode bipolar I disorder: indications for early intervention. *Am J Psychiatry.* 2005; 162(5):1008–10. [PubMed: 15863809]
138. Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE Jr. et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. *Arch Gen Psychiatry.* 2007; 64(1):57–64. [PubMed: 17199055]
139. Bortolato M, Bini V, Tambaro S. Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis. *Pharmaceuticals.* 2010; 3(9):2799–820.
140. Thomas H. A community survey of adverse effects of cannabis use. *Drug Alcohol Depend.* 1996; 42(3):201–7. [PubMed: 8912803]



141. Atha, MJ.; Blanchard, S. Regular Users - Self-reported drug consumption patterns and attitudes to drugs among 1333 regular cannabis users. Independent Drug Monitoring Unit; UK: 1997.
142. D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2004; 29(8):1558–72. [PubMed: 15173844]
143. Favrat B, Menetrey A, Augsburg M, Rothuizen LE, Appenzeller M, Buclin T, et al. Two cases of “cannabis acute psychosis” following the administration of oral cannabis. *BMC Psychiatry*. 2005; 5:17. [PubMed: 15804348]
144. Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR, Fischman MW. A single dose study of nabilone, a synthetic cannabinoid. *Psychopharmacology*. 1980; 71(2):137–42. [PubMed: 6108592]
145. Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. *J Clin Pharmacol*. 1981; 21(8-9 Suppl):377S–82S. [PubMed: 6117575]
146. Schifano F, Corozza O, Deluca P, Davey Z, Di Furia L, Farre M, et al. Psychoactive drug or mystical incense? Overview of the online available information on Spice products. *International Journal of Culture and Mental Health*. 2009; 2(2):137–44.
147. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? *J Mass Spectrom*. 2009; 44(5):832–7. [PubMed: 19189348]
148. Bebartha SV, Varney S, Sessions D, Barry D, Borys D. Spice: A New “Legal” Herbal Mixture Abused by Young Active Duty Military Personnel. *Clinical Toxicology*. 2010; 48(6):632–3.
149. Muller H, Sperling W, Kohrman M, Huttner HB, Kornhuber J, Maler JM. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. *Schizophr Res*. 2010; 118(1-3):309–10. [PubMed: 20056392]
150. Schneir AB, Cullen J, Ly BT. “Spice” girls: synthetic cannabinoid intoxication. *J Emerg Med*. 2011; 40(3):296–9. [PubMed: 21167669]
151. Benford DM, Caplan JP. Psychiatric sequelae of spice, K2, and synthetic cannabinoid receptor agonists. *Psychosomatics*. 2011; 52(3):295. [PubMed: 21565605]
152. Braida D, Limonta V, Malabarba L, Zani A, Sala M. 5-HT1A receptors are involved in the anxiolytic effect of Delta9-tetrahydrocannabinol and AM 404, the anandamide transport inhibitor, in Sprague-Dawley rats. *Eur J Pharmacol*. 2007; 555(2-3):156–63. [PubMed: 17116299]
153. Valjent E, Mitchell JM, Besson MJ, Caboche J, Maldonado R. Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine. *Br J Pharmacol*. 2002; 135(2):564–78. [PubMed: 11815392]
154. Berrendero F, Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. *Psychopharmacology*. 2002; 163(1):111–7. [PubMed: 12185408]
155. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. *J Pharmacol Exp Ther*. 2006; 318(1):304–11. [PubMed: 16569753]
156. Haller J, Varga B, Ledent C, Freund TF. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. *Behavioural pharmacology*. 2004; 15(4):299–304. [PubMed: 15252281]
157. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. *J Pharmacol Exp Ther*. 1990; 253(3):1002–9. [PubMed: 2162942]
158. McGregor IS, Issakidis CN, Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. *Pharmacol Biochem Behav*. 1996; 53(3):657–64. [PubMed: 8866969]
159. Rodriguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, et al. Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. *J Pharmacol Exp Ther*. 1996; 276(1):56–64. [PubMed: 8558457]

160. Marco EM, Perez-Alvarez L, Borcel E, Rubio M, Guaza C, Ambrosio E, et al. Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. *Behavioural pharmacology*. 2004; 15(1):21–7. [PubMed: 15075623]
161. Celerier E, Ahdepil T, Wikander H, Berrendero F, Nyberg F, Maldonado R. Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence. *Neuropharmacology*. 2006; 50(7):788–806. [PubMed: 16443242]
162. Genn RF, Tucci S, Marco EM, Viveros MP, File SE. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. *Pharmacol Biochem Behav*. 2004; 77(3):567–73. [PubMed: 15006468]
163. Bortolato M, Piomelli D. Chapter 4. 5 The endocannabinoid system and anxiety responses. *Handbook of Behavioral Neuroscience*. Elsevier. 2008:303–324.
164. Crippa JA, Zuardi AW, Martin-Santos R, Bhattacharyya S, Atakan Z, McGuire P, et al. Cannabis and anxiety: a critical review of the evidence. *Hum Psychopharmacol*. 2009; 24(7):515–23. [PubMed: 19693792]
165. Katona I, Sperlagh B, Sik A, Kafalvi A, Vizi ES, Mackie K, et al. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 1999; 19(11):4544–58. [PubMed: 10341254]
166. Azad SC, Monory K, Marsicano G, Cravatt BF, Lutz B, Zieglgansberger W, et al. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2004; 24(44):9953–61. [PubMed: 15525780]
167. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. *Neuropharmacology*. 2007; 52(3):958–65. [PubMed: 17156799]
168. Allen, JRA.; Amegadzie, AK.; Gardinier, KM.; Gregory, GS.; Hitchcock, SA.; Hoogstraat, SA., et al. CB1 Modulator compounds. 2008. US7595339
169. Josephus, LHM.; Henderik, WC.; Cornelis, GK. Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity. 2009. US7524867
170. Despres JP, Ross R, Boka G, Almeras N, Lemieux I, ADAGIO-Lipids Investigator. Effect of Rimonabant on the High-Triglyceride/Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat. *Arterioscler Thromb Vasc Biol*. 2009; 29(3):416–23. [PubMed: 19112166]
171. Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. *Cochrane Database Syst Rev*. 2007; 3:CD005353. [PubMed: 17636794]
172. Navarro M, Hernandez E, Munoz RM, del Arco I, Villanua MA, Carrera MR, et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. *Neuroreport*. 1997; 8(2):491–6. [PubMed: 9080435]
173. Arevalo C, de Miguel R, Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. *Pharmacol Biochem Behav*. 2001; 70(1):123–31. [PubMed: 11566149]
174. Patel S, Cravatt BF, Hillard CJ. Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2005; 30(3):497–507. [PubMed: 15280883]
175. Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, et al. Anxiolytic-like properties of the anandamide transport inhibitor AM404. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2006; 31(12):2652–9. [PubMed: 16541083]
176. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. *Lancet*. 2005; 365(9468):1389–97. [PubMed: 15836887]

177. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. *Lancet*. 2007; 370(9600): 1706–13. [PubMed: 18022033]
178. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. *BMJ*. 2007; 335(7631):1194–9. [PubMed: 18006966]
179. Van Gaal LF, Scheen AJ, Rissanen AM, Rossner S, Hanotin C, Ziegler O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. *Eur Heart J*. 2008; 29(14):1761–71. [PubMed: 18417461]
180. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. *Life sciences*. 2005; 76(12):1307–24. [PubMed: 15670612]
181. Greig, IR.; Ross, RA.; Pertwee, RG. 1,5-diaryl-pyrazoles as cannabinoid receptor neutral antagonists useful as therapeutic agents. 2010. US0022611
182. Sink KS, Segovia KN, Collins LE, Markus EJ, Vemuri VK, Makriyannis A, et al. The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. *Pharmacol Biochem Behav*. 2010; 95(4):479–84. [PubMed: 20347865]
183. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. *J Neurosci*. 2003; 23(35):11136–41. [PubMed: 14657172]
184. Benito C, Romero JP, Tolon RM, Clemente D, Docagne F, Hillard CJ, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. *J Neurosci*. 2007; 27(9):2396–402. [PubMed: 17329437]
185. Yiangou Y, Facer P, Durrenberger P, Chessell IP, Naylor A, Bountra C, et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. *BMC Neurol*. 2006; 6:12. [PubMed: 16512913]
186. Onaivi ES, Ishiguro H, Gong JP, Patel S, Meozzi PA, Myers L, et al. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. *PLoS One*. 2008; 3(2):e1640. [PubMed: 18286196]
187. Garcia-Gutierrez MS, Manzanares J. Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. *J Psychopharmacol*. 2011; 25(1):111–20. [PubMed: 20837564]
188. Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, et al. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2010; 35(3):764–74. [PubMed: 19924114]
189. Zuardi AW, Finkelfarb E, Bueno OF, Musty RE, Karniol IG. Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol. *Archives internationales de pharmacodynamie et de therapie*. 1981; 249(1):137–46. [PubMed: 6261703]
190. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR, et al. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. *Drug and alcohol dependence*. 2008; 94(1-3):191–8. [PubMed: 18206320]
191. Malone DT, Jongejan D, Taylor DA. Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats. *Pharmacology, biochemistry, and behavior*. 2009; 93(2):91–6.
192. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. *Psychopharmacology*. 1982; 76(3): 245–50. [PubMed: 6285406]
193. Reid MJ, Bornheim LM. Cannabinoid-induced alterations in brain disposition of drugs of abuse. *Biochemical pharmacology*. 2001; 61(11):1357–67. [PubMed: 11331071]
194. Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K, et al. Cannabidiol potentiates pharmacological effects of Delta(9)-tetrahydrocannabinol via CB(1) receptor-dependent mechanism. *Brain research*. 2008; 1188:157–64. [PubMed: 18021759]


195. Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, et al. Cannabidiol potentiates Delta(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. *Psychopharmacology*. 2011
196. Bornheim LM, Correia MA. Selective inactivation of mouse liver cytochrome P-450III<sub>A</sub> by cannabidiol. *Molecular pharmacology*. 1990; 38(3):319–26. [PubMed: 2402224]
197. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. *Drug metabolism and disposition: the biological fate of chemicals*. 1995; 23(8):825–31. [PubMed: 7493549]
198. Zuardi AW, Karniol IG. Effects on variable-interval performance in rats of delta 9-tetrahydrocannabinol and cannabidiol, separately and in combination. *Braz J Med Biol Res*. 1983; 16(2):141–6. [PubMed: 6317104]
199. Musty, RE.; Conti, LH.; Mechoulam, R. Anxiolytic properties of cannabidiol. In: Harvey, DJ., editor. *Marihuana '84. Proceedings of the Oxford Symposium on Cannabis*. IRL Press Limited; Oxford, UK: 1984. p. 713-719.
200. Guimaraes FS, Chiaretti TM, Graeff FG, Zuardi AW. Antianxiety effect of cannabidiol in the elevated plus-maze. *Psychopharmacology*. 1990; 100(4):558–9. [PubMed: 1969666]
201. Casarotto PC, Gomes FV, Resstel LB, Guimaraes FS. Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. *Behavioural pharmacology*. 2010; 21(4):353–8. [PubMed: 20695034]
202. Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2011; 36(6):1219–26. [PubMed: 21307846]
203. Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. *J Psychopharmacol*. 2011; 25(1):121–30. [PubMed: 20829306]
204. Moreira FA, Aguiar DC, Guimaraes FS. Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. *Prog Neuropsychopharmacol Biol Psychiatry*. 2006; 30(8):1466–71. [PubMed: 16876926]
205. Silveira Filho NG, Tufik S. Comparative effects between cannabidiol and diazepam on neophobia, food intake and conflict behavior. *Research Communications in Psychology, Psychiatry and Behavior*. 1981; 6:25–6.
206. Gomes FV, Casarotto PC, Resstel LB, Guimaraes FS. Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011; 35(2):434–8. [PubMed: 21111767]
207. Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt SJ, Allen P, Martin-Santos R, et al. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. *Arch Gen Psychiatry*. 2009; 66(1):95–105. [PubMed: 19124693]
208. Campos AC, Guimaraes FS. Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. *Psychopharmacology*. 2008; 199(2):223–30. [PubMed: 18446323]
209. de Paula Soares V, Campos AC, Bortoli VC, Zangrossi H Jr, Guimaraes FS, Zuardi AW. Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. *Behavioural brain research*. 2010; 213(2):225–9. [PubMed: 20457188]
210. Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. *Biological psychiatry*. 2007; 62(10):1103–10. [PubMed: 17511970]
211. Glaser ST, Abumrad NA, Fatade F, Kaczocha M, Studholme KM, Deutsch DG. Evidence against the presence of an anandamide transporter. *Proceedings of the National Academy of Sciences of the United States of America*. 2003; 100(7):4269–74. [PubMed: 12655057]
212. Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying BP, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102(49):17852–7. [PubMed: 16314570]

213. Davis, MR.; Ressler, KJ.; Chhatwal, JP.; McDevitt, JP. Augmentation of psychotherapy with cannabinoid reuptake inhibitors. 2006. US0084659
214. Panlilio LV, Justinova Z, Goldberg SR. Animal models of cannabinoid reward. *Br J Pharmacol*. 2010; 160(3):499–510. [PubMed: 20590560]
215. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. *Nat Med*. 2003; 9(1):76–81. [PubMed: 12461523]
216. Patel S, Roelke CT, Rademacher DJ, Cullinan WE, Hillard CJ. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. *Endocrinology*. 2004; 145(12):5431–8. [PubMed: 15331569]
217. Gaetani S, Dipasquale P, Romano A, Righetti L, Cassano T, Piomelli D, et al. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. *Int Rev Neurobiol*. 2009; 85:57–72. [PubMed: 19607961]
218. Naidu PS, Booker L, Cravatt BF, Lichtman AH. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. *J Pharmacol Exp Ther*. 2009; 329(1):48–56. [PubMed: 19118134]
219. Lisboa SF, Resstel LB, Aguiar DC, Guimaraes FS. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. *Eur J Pharmacol*. 2008; 593(1-3):73–8. [PubMed: 18691568]
220. Rubino T, Realini N, Castiglioni C, Guidali C, Vigano D, Marras E, et al. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. *Cereb Cortex*. 2008; 18(6):1292–301. [PubMed: 17921459]
221. Haller J, Barna I, Barsvari B, Gyimesi Pelczer K, Yasar S, Panlilio LV, et al. Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. *Psychopharmacology*. 2009; 204(4):607–16. [PubMed: 19259645]
222. Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. *Biological psychiatry*. 2008; 64(11):930–7. [PubMed: 18814866]
223. Vandevoorde S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. *Curr Top Med Chem*. 2008; 8(3):247–67. [PubMed: 18289091]
224. Clapper JR, Vacondio F, King AR, Duranti A, Tontini A, Silva C, et al. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. *ChemMedChem*. 2009; 4(9):1505–13. [PubMed: 19637155]
225. Sing-Yuen, SK.; Ka, X.; Hongfeng, D. (Oxime)carbamoyl fatty acid amide hydrolase inhibitors. 2005. US6949574
226. Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. *Biochemistry*. 2007; 46(45):13019–30. [PubMed: 17949010]
227. Seillier A, Advani T, Cassano T, Hensler JG, Giuffrida A. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats. *Int J Neuropsychopharmacol*. 2010; 13(3):373–86. [PubMed: 19607756]
228. Sokolic L, Long LE, Hunt GE, Arnold JC, McGregor IS. Disruptive effects of the prototypical cannabinoid Delta-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats. *Behavioural pharmacology*. 2011; 22(3):191–202. [PubMed: 21512341]
229. Sciolino NR, Zhou W, Hohmann AG. Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. *Pharmacol Res*. 2011; 64(3):226–34. [PubMed: 21600985]
230. Kinsey SG, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH. Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay. *Pharmacol Biochem Behav*. 2011; 98(1):21–7. [PubMed: 21145341]




231. Sutt S, Raud S, Areda T, Reimets A, Koks S, Vasar E. Cat odour-induced anxiety--a study of the involvement of the endocannabinoid system. *Psychopharmacology*. 2008; 198(4):509–20. [PubMed: 17882402]
232. Suarez J, Rivera P, Llorente R, Romero-Zerbo SY, Bermudez-Silva FJ, de Fonseca FR, et al. Early maternal deprivation induces changes on the expression of 2-AG biosynthesis and degradation enzymes in neonatal rat hippocampus. *Brain research*. 2010; 1349:162–73. [PubMed: 20599824]
233. Olmstead, MC.; Paquette, JJ. Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist. 2007. US0060638
234. Aragona M, Onesti E, Tomassini V, Conte A, Gupta S, Gilio F, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. *Clin Neuropharmacol*. 2009; 32(1):41–7. [PubMed: 18978501]
235. Karschner EL, Darwin WD, McMahan RP, Liu F, Wright S, Goodwin RS, et al. Subjective and physiological effects after controlled Sativex and oral THC administration. *Clin Pharmacol Ther*. 2011; 89(3):400–7. [PubMed: 21289620]
236. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. *Proc Natl Acad Sci U S A*. 2009; 106(48):20270–5. [PubMed: 19918051]
237. Justinova Z, Yasar S, Redhi GH, Goldberg SR. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. *J Neurosci*. 2011; 31(19):7043–8. [PubMed: 21562266]
238. Weil AT, Zinberg NE, Nelsen JM. Clinical and psychological effects of marihuana in man. *Science*. 1968; 162(3859):1234–42. [PubMed: 4880784]
239. Jones RT. Marihuana-induced “high”: influence of expectation, setting and previous drug experience. *Pharmacol Rev*. 1971; 23(4):359–69. [PubMed: 4943950]
240. Tennant FS Jr. Groesbeck CJ. Psychiatric effects of hashish. *Arch Gen Psychiatry*. 1972; 27(1): 133–6. [PubMed: 5032722]
241. Millman RB, Sbriglio R. Patterns of use and psychopathology in chronic marijuana users. *Psychiatr Clin North Am*. 1986; 9(3):533–45. [PubMed: 3022257]
242. Dorard G, Berthoz S, Haviland MG, Phan O, Corcos M, Bungener C. Multimethod alexithymia assessment in adolescents and young adults with a cannabis use disorder. *Compr Psychiatry*. 2008; 49(6):585–92. [PubMed: 18970907]
243. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. *J Clin Pharmacol*. 1981; 21(8-9 Suppl):143S–52S. [PubMed: 6271820]
244. Ashton CH. Adverse effects of cannabis and cannabinoids. *Br J Anaesth*. 1999; 83(4):637–49. [PubMed: 10673884]
245. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. *Brain research*. 1993; 616(1-2):293–302. [PubMed: 8395305]
246. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. *Pharmacol Biochem Behav*. 1994; 47(1):33–40. [PubMed: 8115426]
247. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. *Schizophrenia bulletin*. 2008; 34(6):1111–21. [PubMed: 18723841]
248. Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: the hash realities. *Nature reviews Neuroscience*. 2007; 8(11):885–95.
249. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. *The British journal of psychiatry: the journal of mental science*. 2004; 184:110–7. [PubMed: 14754822]
250. Houston JE, Murphy J, Adamson G, Stringer M, Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the National Comorbidity Survey. *Schizophrenia bulletin*. 2008; 34(3):580–5. [PubMed: 18024467]


251. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. *Biological psychiatry*. 2005; 57(10):1117–27. [PubMed: 15866551]
252. Henquet C, Rosa A, Delespaul P, Papiol S, Fananas L, van Os J, et al. COMT ValMet moderation of cannabis-induced psychosis: a momentary assessment study of ‘switching on’ hallucinations in the flow of daily life. *Acta psychiatrica Scandinavica*. 2009; 119(2):156–60. [PubMed: 18808401]
253. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. *Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology*. 2006; 31(12):2748–57. [PubMed: 16936704]
254. Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. *Psychopharmacology*. 2007; 192(3):325–36. [PubMed: 17333138]
255. Boucher AA, Hunt GE, Micheau J, Huang X, McGregor IS, Karl T, et al. The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. *Int J Neuropsychopharmacol*. 2011; 14(5):631–43. [PubMed: 20701826]
256. Khare M, Taylor AH, Konje JC, Bell SC. Delta9-tetrahydrocannabinol inhibits cytotrophoblast cell proliferation and modulates gene transcription. *Molecular human reproduction*. 2006; 12(5): 321–33. [PubMed: 16597638]



**Fig. 1.** Chemical structures of the major phytocannabinoids. For more details, see text.






**Fig. 2.** Chemical structures of the synthetic THC analogs CP55,940, CP55,244, CP 47,497 and HU-210. For more details, see text.



**Fig. 3.** Chemical structures of the major endocannabinoids. For more details, see text.



**AM404****URB597****JZL184**

**Fig. 4.** Chemical structures of endocannabinoid degradation inactivators. For more details, see text.

**Table 1**  
**Current pharmacological strategies for the treatment of anxiety disorders**

---

<b>1</b>	Generalized anxiety disorder
	<b>a.</b> Benzodiazepines
	<b>b.</b> Buspirone
	<b>c.</b> Selective serotonin reuptake inhibitors
<b>2</b>	Panic attack
	<b>a.</b> High-potency benzodiazepines
	<b>b.</b> Tricyclic antidepressants
	<b>c.</b> Selective serotonin reuptake inhibitors
	<b>d.</b> Monoamine oxidase inhibitors
<b>3</b>	Post-traumatic stress disorder
	<b>a.</b> Selective serotonin reuptake inhibitors
	<b>b.</b> Low-dose antipsychotic agents
<b>4</b>	Obsessive-compulsive disorder
	<b>a.</b> Tricyclic antidepressants
	<b>b.</b> Selective serotonin reuptake inhibitors

---

**Table 2**  
**Paradigms for testing of anxiety-like behaviors in rodents**

---

<b>1</b>	<b>Unconditioned anxiety</b>
	<b>a.</b> Tests for social anxiety
	<b>i.</b> Maternal separation-induced ultrasonic vocalizations (for pups)
	<b>ii.</b> Social interaction
	<b>b.</b> Tests based on approach/avoidance conflict
	<b>i.</b> Novel open field
	<b>ii.</b> Defensive withdrawal
	<b>iii.</b> Elevated plus maze
	<b>iv.</b> Elevated T-maze
	<b>v.</b> Zero maze
	<b>vi.</b> Light/dark box
	<b>vii.</b> Emergence test
	<b>c.</b> Tests based on antipredator defensive behavior
	<b>i.</b> Mouse defense test battery
	<b>ii.</b> Predator urine exposure test
	<b>iii.</b> Predator exposure test
	<b>d.</b> Other tests
	<b>i.</b> Novelty-induced feeding suppression
	<b>ii.</b> Marble burying
	<b>iii.</b> Defensive burying
<b>2</b>	<b>Conditioned anxiety</b>
	<b>a.</b> Tests on conditional fear
	<b>i.</b> Fear- conditioned freezing
	<b>ii.</b> Fear-potentiated startle
	<b>iii.</b> Conditional fear-induced analgesia
	<b>b.</b> Operant conflict test
	<b>i.</b> Geiller-Seifter test (conditioned suppression of eating)
	<b>ii.</b> Vogel test (conditioned suppression of drinking)

---